Specialty
Aesthetics Cardiology Cataract & Refractive Dermatology General Ophthalmology Glaucoma Optometry Retina Women's Health View All Courses
Course Type
Evaluation Supplement Multimedia Webinar Podcast In-Person Multi-part Collection
Search
Login

Dry Eye Flares Consensus Statement: Treating Flares vs. Chronic Dry Eye Disease Part 3

By: Preeya K. Gupta, MD; Eric D. Donnenfeld, MD

This course has expired. You can still review the content but course credit is no longer available.

Webinar Credits: 0.25

Drs. Eric D. Donnenfeld and Preeya K. Gupta discuss strategies to treat dry eye patients, as compared to patients with dry eye flares. This is Part 3 of 3.

Expiration Date: Friday, July 29, 2022
Release Date: July 29, 2021

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Discuss strategies to treat dry eye patients, as compared to patients with dry eye flares

Accreditation and Designation Statement

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC (Evolve) and The Fundingsland Group. Evolve is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Evolve Medical Education designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+

Faculty and Disclosures

Preeya K. Gupta, MD

Founder and Director of Triangle Eye Consultants

Wake Forest and Cary, North Carolina

Eric D. Donnenfeld, MD

Ophthalmic Consultants of Long Island and Connecticut
Trustee, Dartmouth Medical School
Clinical Professor of Ophthalmology
New York University
New York, New York

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Preeya K. Gupta, MD, has no financial agreements with commercial interests.

Eric D. Donnenfeld, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allegro, Allergan , Alcon Vision, Avellino Labs, Bausch + Lomb, Carl Zeiss Meditec, CorneaGen, Covalent, BVI, Blephex, Dompé, ELT Sight, EyePoint Pharma, Foresight, Glaukos, Ivantis, Johnson & Johnson Vision, Kala Pharmaceuticals, Katena, Lacripen, LensGen, Mati Therapeutics, MDBackline, Merck, Mimetogen, Nanowafer, Novabay, Novartis, Novaliq, Ocular Innovations, Oculis, Odyssey, Omega Ophthalmics, Oyster Point Pharma, Pfizer, Pogotec, Ocuhub, Omeros, PRN, RegenerEyes, ReTear, RPS, Shire, Strathspey Crown, Sun Pharma, Surface, Tarsus, Tearlab, Tearscience, Thea, TLC Laser Centers, Veracity, Versant Ventures, Visionary Venture, and Visus Therapeutics.  Stock/Shareholder: Avedro, CorneaGen, Covalent, ELT Sight, EyePoint Pharma Glaukos, Ivantis, Lacripen, LensGen, Mati Therapeutics, MDBackline, Mimetogen, Novabay, Ocuhub, Ocular Innovations Oculis, Orasis Pogotec, RegenerEyes, ReTear, RPS , Strathspey Crown, Surface, Tarsus, Tearlab, Veracity, Versant Ventures, Visionary Ventures, and Visus Therapeutics.

The staff and planners from Evolve and The Fundingsland Group have no financial relationships with commercial interests.  Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group or Kala Pharmaceuticals.

Begin Course